首页 | 本学科首页   官方微博 | 高级检索  
     


Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First‐Line Docetaxel: A Multicenter,Randomized, Double‐Blind,Placebo‐Controlled Trial (SAKK 08/11)
Authors:Richard Cathomas  Simon J. Crabb  Michael Mark  Ralph Winterhalder  Christian Rothermundt  Tony Elliott  Philippe von Burg  Heike Kenner  Stefanie Hayoz  Simona Berardi Vilei  Daniel Rauch  Enrico Roggero  Markus G. Mohaupt  Jürg Bernhard  Gabriela Manetsch  Silke Gillessen  for the Swiss Group for Clinical Cancer Research SAKK
Affiliation:1. Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland;2. Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom;3. Department of Oncology Kantonsspital Luzern, Luzern, Switzerland;4. Department of Oncology/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland;5. Department of Oncology, The Christie Clinic, Manchester, United Kingdom;6. Department of Oncology, Kantonsspital Aargau, Aarau, Switzerland;7. SAKK Coordinating Center, Bern, Switzerland;8. Oncology, Hospital Simmental, Thun, Switzerland;9. Department of Oncology, Bellinzona IOSI, Bellinzona, Switzerland;10. Department of Nephrology, Hypertension and Clinical Pharmacology, University of Bern, Bern, Switzerland;11. International Breast Cancer Study Group Coordinating Center Bern and University Hospital, Inselspital Bern, Switzerland
Abstract:
Keywords:castration‐resistant prostate cancer  orteronel  maintenance  docetaxel
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号